Oxford-AstraZeneca vaccine
Also known as Vaxzevria, this COVID-19 vaccine was developed by AstraZeneca and the University of Oxford, being a two-dose vaccine just like Pfizer and Moderna. After receiving the two doses, AstraZeneca’s clinical trials concluded that the vaccine has a 76% efficacy rate.
The vaccine is also a viral vector one (like Johnson & Johnson’s), and the World Health Organization authorized it in mid-February. However, as people started to get their Oxford-AstraZeneca doses, controversies surrounding this vaccine arose.
There has been a number of blood clotting incidents linked to the Oxford-AstraZeneca vaccine. Some of them were fatal.
Yet, health authorities say that the benefits of the vaccine outweigh the number of blood clotting cases.
You might also like: 10 Signs You’ve Already Had Coronavirus
